source
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trialCerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the ca…
- Optogenetics therapy restores light sensitivity in half of retinitis pigmentosa patients in early trialA small clinical study examined an optogenetics‑based approach for treating retinitis pigmentosa, a genetic disorder that progressively destroys retinal light‑sensing cells and often leads to legal…